PMID- 33015325
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2364-3722 (Print)
IS  - 2196-9736 (Electronic)
IS  - 2196-9736 (Linking)
VI  - 8
IP  - 10
DP  - 2020 Oct
TI  - Efficacy of EUS-RFA in pancreatic tumors: Is it ready for prime time? A 
      systematic review and meta-analysis.
PG  - E1243-E1251
LID - 10.1055/a-1221-5012 [doi]
AB  - Background and study aims  Endoscopic ultrasound-guided radiofrequency ablation 
      (EUS-RFA) can be used in patients with unresectable pancreatic ductal 
      adenocarcinoma (PDAC). We performed a systematic review and meta-analysis to 
      evaluate the efficacy of EUS-RFA in treatment of locally advanced unresectable 
      PDAC and other pancreatic tumors. Patients and methods  A comprehensive search 
      was done of multiple electronic databases and conference proceedings including 
      PubMed, EMBASE, Web of Science databases, Google Scholar and manual search of 
      references (from inception through May 2019) to identify the studies reporting 
      use of EUS-RFA for pancreatic lesions. The primary outcome was to evaluate 
      technical and clinical success of the procedure. The secondary outcome was to 
      study overall adverse events (AEs). Results  Thirteen studies reporting 165 
      EUS-RFA procedures on 134 patients were included. Of 134 patients, 27.94 % (38) 
      had unresectable locally advanced PDAC, 40 % (53) had PNETs, 3 % (4) had 
      metastasis to the pancreas and 30 % (41) had other lesions. The pooled technical 
      success rate calculated out of the total number of procedures was 100 % (95 % CI 
      [99.18 - 100], I2 = 0 %). The pooled clinical success rate calculated out of the 
      total number of patients was 91.58 % (95 % CI [82.5 - 98.08], I2 = 21.5 %). The 
      pooled overall AE rates were 14.67 % (95 % CI [4.77 - 27.46], I2 = 56.19 %) out 
      of which abdominal pain was the most common with 9.82 % (95 % CI [3.34 - 18.24], 
      I2 = 23.76 %). Low to moderate heterogeneity was noted. Conclusion  EUS-RFA has 
      high technical (100 %) and clinical success (91.5 %) rates. Further multicenter 
      trials are needed to further validate our findings.
CI  - The Author(s). This is an open access article published by Thieme under the terms 
      of the Creative Commons Attribution-NonDerivative-NonCommercial License, 
      permitting copying and reproduction so long as the original work is given 
      appropriate credit. Contents may not be used for commecial purposes, or adapted, 
      remixed, transformed or built upon. 
      (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Dhaliwal, Amaninder
AU  - Dhaliwal A
AD  - Division of Gastroenterology and Hepatology, University of Nebraska Medical 
      Center, Omaha, Nebraska, United States.
FAU - Kolli, Sindhura
AU  - Kolli S
AD  - Department of Bariatrics, NYU Langone Medical Center, New York, New York, United 
      States.
FAU - Dhindsa, Banreet Singhg
AU  - Dhindsa BS
AD  - Department of Internal Medicine, University of Nevada Las Vegas School of 
      Medicine, Las Vegas, Nevada, United States.
FAU - Choa, Jacqueline
AU  - Choa J
AD  - Department of Internal Medicine, University of Nevada Las Vegas School of 
      Medicine, Las Vegas, Nevada, United States.
FAU - Mashiana, Harmeet Singh
AU  - Mashiana HS
AD  - Division of Gastroenterology and Hepatology, University of Nebraska Medical 
      Center, Omaha, Nebraska, United States.
FAU - Ramai, Daryl
AU  - Ramai D
AD  - Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New 
      York, United States.
FAU - Chandan, Saurabh
AU  - Chandan S
AD  - Division of Gastroenterology and Hepatology, University of Nebraska Medical 
      Center, Omaha, Nebraska, United States.
FAU - Bhogal, Neil
AU  - Bhogal N
AD  - Division of Gastroenterology and Hepatology, University of Nebraska Medical 
      Center, Omaha, Nebraska, United States.
FAU - Sayles, Harlan
AU  - Sayles H
AD  - Department of Biostatistics, University of Nebraska Medical Center, Omaha, 
      Nebraska, United States.
FAU - Bhat, Ishfaq
AU  - Bhat I
AD  - Division of Gastroenterology and Hepatology, University of Nebraska Medical 
      Center, Omaha, Nebraska, United States.
FAU - Singh, Shailender
AU  - Singh S
AD  - Division of Gastroenterology and Hepatology, University of Nebraska Medical 
      Center, Omaha, Nebraska, United States.
FAU - Adler, Douglas G
AU  - Adler DG
AD  - University of Utah School of Medicine, Gastroenterology and Hepatology, Salt Lake 
      City, Utah, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200922
PL  - Germany
TA  - Endosc Int Open
JT  - Endoscopy international open
JID - 101639919
PMC - PMC7508651
COIS- Competing interests The authors declare that they have no conflict of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
PMCR- 2020/10/01
CRDT- 2020/10/05 06:22
PHST- 2020/04/16 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - 10.1055/a-1221-5012 [doi]
PST - ppublish
SO  - Endosc Int Open. 2020 Oct;8(10):E1243-E1251. doi: 10.1055/a-1221-5012. Epub 2020 
      Sep 22.